JP2024501316A - 構造的に無秩序な配列に特異的な抗体 - Google Patents

構造的に無秩序な配列に特異的な抗体 Download PDF

Info

Publication number
JP2024501316A
JP2024501316A JP2023539757A JP2023539757A JP2024501316A JP 2024501316 A JP2024501316 A JP 2024501316A JP 2023539757 A JP2023539757 A JP 2023539757A JP 2023539757 A JP2023539757 A JP 2023539757A JP 2024501316 A JP2024501316 A JP 2024501316A
Authority
JP
Japan
Prior art keywords
mab
seq
antigen
cdr
pas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501316A5 (https=
Inventor
シュルツ，ヨナス
ビンデル，ウーリ
フリードリッヒ，ラース
ゲバウアー，ミカエラ
シュラプシー，マルティン
スケラ，アルネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of JP2024501316A publication Critical patent/JP2024501316A/ja
Publication of JP2024501316A5 publication Critical patent/JP2024501316A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023539757A 2020-12-22 2021-12-22 構造的に無秩序な配列に特異的な抗体 Pending JP2024501316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20216744.1 2020-12-22
EP20216744 2020-12-22
PCT/EP2021/087365 WO2022136582A1 (en) 2020-12-22 2021-12-22 Antibodies specific for structurally disordered sequences

Publications (2)

Publication Number Publication Date
JP2024501316A true JP2024501316A (ja) 2024-01-11
JP2024501316A5 JP2024501316A5 (https=) 2024-12-27

Family

ID=73856935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539757A Pending JP2024501316A (ja) 2020-12-22 2021-12-22 構造的に無秩序な配列に特異的な抗体

Country Status (9)

Country Link
US (1) US20240294632A1 (https=)
EP (1) EP4267628A1 (https=)
JP (1) JP2024501316A (https=)
KR (1) KR20230124637A (https=)
CN (1) CN117120476A (https=)
AU (1) AU2021405029A1 (https=)
CA (1) CA3200238A1 (https=)
IL (1) IL303816A (https=)
WO (1) WO2022136582A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118146384A (zh) * 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
EP4602053A2 (en) * 2022-10-14 2025-08-20 Aikium Inc. Protein scaffolds for disordered regions
WO2025088192A1 (en) * 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
CN117683866B (zh) * 2024-01-22 2024-08-06 湛江中心人民医院 检测细胞中dna的方法
CN118290585B (zh) * 2024-06-04 2024-08-30 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502711A (ja) * 2016-01-06 2019-01-31 ケンブリッジ・エンタープライズ・リミテッドＣａｍｂｒｉｄｇｅ Ｅｎｔｅｒｐｒｉｓｅ Ｌｉｍｉｔｅｄ 反応速度論に基づく新規なタンパク質凝集阻害剤の特定方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
WO2017109087A1 (en) 2015-12-22 2017-06-29 Xl-Protein Gmbh Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
CN110891612A (zh) 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 蛋白质药物与p/a肽的缀合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502711A (ja) * 2016-01-06 2019-01-31 ケンブリッジ・エンタープライズ・リミテッドＣａｍｂｒｉｄｇｅ Ｅｎｔｅｒｐｒｉｓｅ Ｌｉｍｉｔｅｄ 反応速度論に基づく新規なタンパク質凝集阻害剤の特定方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOMATERIALS, vol. 241, JPN6025046789, May 2020 (2020-05-01), pages 119903 - 1, ISSN: 0005731233 *
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 1, JPN6025046787, 24 December 2020 (2020-12-24), pages 124 - 1, ISSN: 0005731235 *
JOURNAL OF BIOMOLECULAR TECHNIQUES, vol. 18, no. 3, JPN6025046788, 2007, pages 173 - 176, ISSN: 0005731234 *
PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 26, no. 8, JPN7025004939, 2013, pages 489 - 501, ISSN: 0005731232 *

Also Published As

Publication number Publication date
WO2022136582A1 (en) 2022-06-30
EP4267628A1 (en) 2023-11-01
AU2021405029A9 (en) 2025-03-13
AU2021405029A1 (en) 2023-07-20
KR20230124637A (ko) 2023-08-25
US20240294632A1 (en) 2024-09-05
CA3200238A1 (en) 2022-06-30
CN117120476A (zh) 2023-11-24
IL303816A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
JP2024501316A (ja) 構造的に無秩序な配列に特異的な抗体
US12275789B2 (en) Human antibodies binding to ROR2
KR102355309B1 (ko) 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
Hong et al. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies
JP7798805B2 (ja) 抗ＴＧＦβ抗体及びその治療的使用
JP2013538566A (ja) 改良された抗血清アルブミン結合変異体
AU2022252731B2 (en) Protein Binders For iRhom2
AU2015364687A1 (en) Intercalated single-chain variable fragments
Michigami et al. A “ligand-targeting” peptide-drug conjugate: Targeted intracellular drug delivery by VEGF-binding helix-loop-helix peptides via receptor-mediated endocytosis
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
Schilz et al. Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope
CN115043940A (zh) 抗人血清白蛋白抗体及其应用
WO2019075392A1 (en) ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF
CN116390945A (zh) 无细胞抗体工程化平台和针对SARS-CoV-2的中和抗体
WO2023030511A1 (en) Bi-functional fusion protein and uses thereof
RU2852383C1 (ru) Бифункциональный слитый белок и его применение
RU2784586C2 (ru) Человеческие антитела, связывающиеся с ror2
JP2025508603A (ja) ネコ抗体ライブラリー
WO2021190437A1 (en) Antibodies against areg and its use
KR20250039299A (ko) 항-il-6 도메인 항체
CN121758584A (zh) Pth复合物及其应用
NZ786225A (en) Anti-tnfalpha-antibodies and functional fragments thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260216